NIH Licensing Opportunity: A Class of Small Molecule Phenylalanine Derivatives as Potential Payloads for Cancer-Targeted Delivery Systems

Share Article

This webinar reveals how a revolutionary class of small molecule phenylalanine derivatives can serve as possible payloads for cancer-targeted delivery systems.

Cancer cells

Cancer Cells

The class of small molecule phenylalanine derivatives impede Growth Factor Receptor-Bound Protein 2 activity and hinder cancer cell migration, invasion and angiogenesis.

One Million Solutions in Health announces an opportunity to license science from the NIH which offers potential payloads for cancer- targeted delivery systems.

One Million Solutions in Health has partnered with the United States' National Institutes of Health Office of Technology Transfer (NIH-OTT) and the National Cancer Institute Technology Transfer Center (NCI-TTC) and is seeking to spread awareness of NIH technologies and advances.

In this One Million Solutions in Health webinar entitled “NIH Licensing Opportunity: A Class of Small Molecule Phenylalanine Derivatives as Potential Payloads for Cancer-Targeted Delivery Systems" end users are provided with the opportunity to acquire knowledge about the latest science and technology directly from NIH scientists themselves. Users can also take part in One Million Solutions in Health's exclusive Signature Square process where they are able to assess the innovation, make inquiries and give open feedback to the scientists.

This class of small molecule phenylalanine derivatives impede Growth Factor Receptor-Bound Protein 2 activity and hinder cancer cell migration, invasion and angiogenesis.

The adaptor protein growth factor receptor-bound-2 (Grb2) serves as a key motioning arbitrator of numerous growth factor receptors and intracellular tyrosine kinases that advance cell motility, propagation and morphogenesis.

The act of motioning or signalling is established through a selective, high affinity binding interaction between the Grb2 Src homology type-2 (SH2) domain and specific phosphotyrosyl-containing motifs in activated tyrosine kinases, and permits the creation of multi-molecular signalling complexes that connect kinases to crucial downstream monitoring networks.

By taking advantage of the unique structural features of this relationship, small synthetic peptidomimetic Grb2 SH2 domain adversaries were realistically designed and advanced that bind tightly and selectively to the Grb2 SH2 domain; therefore, the interaction with activated tyrosine kinases can be impeded. These competitive binding adversaries strongly hinder growth factor stimulated cell motility, matrix invasion, and branching morphogenesis in model cultured cell systems. With IC50 values of 30 nM or less, they block angiogenesis in the avian CAM assay, and block tumour metastasis in animal models.

Ultimately, these Grb2 SH2 domain antagonists may possess the power to serve as a payload for cancer-targeted therapeutic delivery systems.

The Technology Evaluation Consortium includes the Signature Square process and consists of organizations such as Pfizer, AbbVie, Amgen and Allergan, and many others.

If you would like to license unique solutions to combat cancer cell migration, invasion and angiogenesis, then this presentation is for you.

ABOUT ONE MILLION SOLUTIONS IN HEALTH

The goal of One Million Solutions in Health™ is to shape health care by sharing solutions and, importantly, to accelerate the discovery, development and delivery ... of innovative cures, treatments and preventative measures for patients around the world.

In this next year, we will be reviewing 1000's of new solutions and new scientific discoveries. By engaging scientists, entrepreneurs, investors, innovators, industry experts, health care professionals, and patients across various disciplines, and from around the world, we can utilize the power of the internet to disrupt things in a positive and transformative way to accelerate the movement of new solutions and scientific discoveries from the scientist to the patient.

We are on our way towards accelerating high-potential innovations, catalyzing investment and increasing awareness of, and support for, transformative ideas to improve health and save lives. By facilitating efforts to ensure organizations can Connect, Learn + Share, Innovate and Collaborate, our vision is to improve health care delivery, accelerate life sciences research, and share patient and consumer-focused ideas and solutions.

As a not-for-profit, we welcome your participation and are thrilled to have you be a part of this transformative journey!

ABOUT THE TECHNOLOGY EVALUATION CONSORTIUM

The Technology Evaluation Consortium™ from One Million Solutions in Health™ is dedicated to improving and accelerating life sciences R&D and health care outcomes. The Technology Evaluation Consortium brings together life sciences and/or health care companies and industry vendors or scientists, and other relevant partners (e.g., government and Universities), to evaluate and validate technologies or services in a collaborative environment.

The model empowers technology providers and scientists, and industry end-users, to collectively assess a number of solutions in a cost-effective manner, producing a depth and breadth of results that no company can achieve alone. Our mission is to triage and streamline new technology consideration for the industry, and to be the place for the industry to conduct their evaluations and validations.

MEDIA CONTACT:
Dawn Van Dam
Executive Director and CEO
dawn.vandam(at)onemillionsolutionsinhealth.org
http://www.onemillionsolutionsinhealth.org

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Dawn Van Dam
@1MilSolutionsIn
since: 04/2012
Follow >
One Million Solutions in Health
since: 06/2012
Like >
One Million Solutions in Health

Follow us on
Visit website